Effect of Niacin Therapy on Cardiovascular Outcomes in Patients With Coronary Artery Disease
Effect Decrease
Trial Design Meta analysis
Trial Length n/a
Number of Subjects 5137
Sex Both Genders
Notes for this study:
In a meta-analysis on seven studies in subjects with coronary artery disease where supplementation of niacin was given alongside a pharmaceutical (usually of the fibrate or statin class), overall supplementation of niacin (relative to the combination of the drug and placebo) appeared to have beneficial effects in reducing incidence of nonfatal myocardial infarction (95% CI 0.603-0.856), coronary artery revascularization (95% CI 0.150-0.628), stroke, and transient ischemic attack (95% CI 0.613-0.940) but missed statistical significance in reducing overall cardiovascular mortality (95% CI of 0.773-1.008).

All studies included used different methodology in regards to which drug was used alongside niacin therapy.